Polskie Towarzystwo Alzheimerowskie

  • Home
  • Polskie Towarzystwo Alzheimerowskie

Polskie Towarzystwo Alzheimerowskie Stowarzyszenie skupiające lekarzy i naukowców zajmujących się leczeniem chorych na chorobę Alzheimera i inne choroby powodujące otępienie.

Polskie Towarzystwo Alzheimerowskie jest stowarzyszeniem powołanym przez lekarzy i naukowców zajmujących się leczeniem chorych na chorobę Alzheimera i inne choroby powodujące zaburzenia funkcji poznawczych (otępienie) oraz naukowymi badaniami przyczyn tych chorób. Celem Towarzystwa jest m.in. wspieranie rozwoju profilaktyki i leczenia chorób mózgu prowadzących do otępienia, inicjowanie i wspieranie badań naukowych oraz upowszechnianie wiedzy w tym zakresie.

Zapraszamy na XVI Konferencję Naukowo-Szkoleniową Polskiego Towarzystwa Alzheimerowskiego, która odbędzie się 30 i 31 ma...
16/05/2025

Zapraszamy na XVI Konferencję Naukowo-Szkoleniową Polskiego Towarzystwa Alzheimerowskiego, która odbędzie się 30 i 31 maja 2025 roku w Warszawie. Zgodnie z tytułem konferencji „Otępienie w Praktyce Klinicznej” przedstawione zostaną najnowsze doniesienia, które mogą być najbardziej przydatne w zapobieganiu, diagnozowaniu i leczeniu choroby Alzheimera i innych typów zaburzeń otępiennych. Program i rejestracja dostępne są pod linkiem: https://konferencje.90c.pl/pta/ #

07/05/2025

For those that have been following the news over the last two years on the regulatory process for the new treatments for Alzheimer’s disease, especially in Europe, you might be interested to read a short article published recently The Lancet “The regulatory rollercoaster continues”.

Read the article to learn more about this ongoing debate: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00833-5/

22/04/2025

Stem Cell Treatment At Swiss Medica

17/04/2025

The recent EU authorisation of lecanemab for the treatment of people with Mild Cognitive Impairment (MCI) in the early stages of Alzheimer’s disease m

17/04/2025

With the EU authorisation of lecanemab for the treatment of Mild Cognitive Impairment (MCI) due to Alzheimer’s disease, health systems are faced with

14/04/2025
02/04/2025

On 1 April, Eisai and Biogen announced that the European Commission has decided to refer the marketing authorisation approval decision of lecanemab in the EU to the Appeal Commi

28/03/2025

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a negative opinion on donanemab, for the treatment of early ’s disease. In its opinion, the CHMP highlighted safety concerns, noting that the benefits of donanemab were not large enough to outweigh the risk of potentially fatal events due to ARIA (amyloid-related imaging abnormalities).

This decision will come as a disappointment to people living with Alzheimer’s disease in Europe, who had hoped for the authorisation of an additional disease-modifying therapy.

Alzheimer Europe welcomes the attention the CHMP pays to patient safety, and was encouraged by the considered approach taken during the evaluation of lecanemab, which aimed to identify patients likely to benefit from treatment whilst excluding those at greatest risk of harmful side-effects. The organisation had hoped that a similar approach would be used for the evaluation of donanemab with a controlled access programme, rigorous safety monitoring requirements and the obligation for the company to conduct a post-authorisation safety study. This was the route chosen by regulators in the US, UK, China and Japan, where donanemab has been authorised.

Alzheimer Europe hopes that findings from real-world studies and ongoing trials of donanemab will provide the necessary scientific evidence for the EMA to reconsider its position.
https://www.alzheimer-europe.org/news/alzheimer-europe-regrets-negative-european-medicines-agency-opinion-donanemab-reduces-choice?language_content_entity=en

28/03/2025

Today, 28 March, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended against granting the marketing authorisation of donanemab (Kisunla) in the treatment of mild cognitive impairment or the mild dementia stage of Alzheimer’s disease across the European Union’s Member States and European Economic Area (EEA).

This is likely to be the second disease modifying therapy to be denied by the bloc, after the EMA declined aducanumab, leaving lecanemab as the only disease modifying therapy likely to achieve marketing authorisation.

Read the update: https://www.alzint.org/news-events/news/emas-chmp-recommends-against-granting-marketing-authorisation-for-donanemab/

23/03/2025

ADI has previously highlighted the challenge of health disparity in emerging treatments for Alzheimer’s disease.

We are now sharing insights from both medical practitioners and people receiving treatments, on the emergence of travelling for treatment, influenced by regulatory disparity or countries where treatment is not available.

In our most recent World Alzheimer Report, ADI found that 93% of the public would seek a diagnosis if treatments were available.

Read our 2024 World Alzheimer Report: https://bit.ly/3XwYtFD

Address


Alerts

Be the first to know and let us send you an email when Polskie Towarzystwo Alzheimerowskie posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Polskie Towarzystwo Alzheimerowskie:

  • Want your practice to be the top-listed Clinic?

Share